P1346
P184
MAP kinase phosphatasesInteraction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammalsDisruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation.High-throughput RNAi screening reveals novel regulators of telomeraseAPRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancerIdentification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancerChromosomal localization of three human dual specificity phosphatase genes (DUSP4, DUSP6, and DUSP7)Structural basis for recruitment of BRCA2 by PALB2Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box moduleCRK7 modifies the MAPK pathway and influences the response to endocrine therapyA conserved family of genes related to the testis determining gene, SRY3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinaseDirect interaction of FANCD2 with BRCA2 in DNA damage response pathwaysDNA binding and bending properties of the post-meiotically expressed Sry-related protein Sox-5Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1Genome-wide association studies identify four ER negative-specific breast cancer risk lociDeterminants of age at menarche in the UK: analyses from the Breakthrough Generations StudyNeuregulin3 alters cell fate in the epidermis and mammary glandAnalysis of PALB2/FANCN-associated breast cancer familiesEstablishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression dataReceptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cellsFunctional and molecular characterisation of mammary side population cellsErratum to: Functional and molecular characterisation of mammary side population cellsRetroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell lineBrca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesisInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerGenome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyRegulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family membersGermline mutations in RAD51D confer susceptibility to ovarian cancerThe human FXY gene is located within Xp22.3: implications for evolution of the mammalian X chromosomeThe mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificityResistance to therapy caused by intragenic deletion in BRCA2Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
P50
Q21999790-EFC25687-9C36-432F-8EF5-7B7CEB6B46B4Q22010135-C984E94E-F094-405D-8B4F-FA43BE8E5FD0Q22242910-F1D3C3DF-0CEA-4DFA-8B26-33AD11B2A120Q24300843-7F92C90B-CD77-4CFF-B9AD-D6F122F5F97BQ24304176-707CE6B0-983E-4D27-8B0B-47289275F6D9Q24309649-6B18F03C-569D-40A9-A58E-D9A763AF492CQ24313653-70CC2242-AFD8-4A0E-BD3F-928D98B14FD6Q24315745-EBFC7F3A-897D-4E82-8C59-6558EE344791Q24319662-8B4E6419-1958-4401-99AC-F4C2F25EDF5EQ24319910-B8BCC035-1D46-483F-BFCA-1D8EC6F9899FQ24320073-B035A59F-00D9-4A21-B5F4-420832889D01Q24321364-814034E2-D5D3-488D-8D7D-BCC85EC74E35Q24336639-79A911EF-D760-4680-B496-D721AD54FFAFQ24338293-DAFFFAD3-9D11-457D-A524-7467C99FFD60Q24562937-1668B157-D58F-4CAC-87B5-1E9600EA59CBQ24596134-388777EE-A354-4F9F-908B-7BDE1AD2BFAAQ24622610-85F2752B-E6EC-44B2-8630-83000E9CF430Q24633288-9D43F646-061D-4158-A746-9370229E4DC5Q24681926-03F2BD28-485A-4565-9227-578A2E06B0ABQ24683771-7DF9AB66-AC59-4DC3-8D27-32C07A7BFEB7Q24684071-ADC66A08-7A8E-48F6-9C2C-0E1F7BB8D6B2Q24792463-3DC38912-3002-454C-9D81-41EF6EB38EBCQ24794990-6E0AAD4D-12A3-4908-BBC1-04B426E5AD97Q24795234-57D44CA2-D2BB-4DE7-9ADA-0B71BF72ABBEQ24803346-F7AF6F3F-3ACD-4DB5-9E37-A6DF66483CF4Q27347240-5826A328-45A9-47F0-A3D9-556C550272C2Q27851474-1CB9C589-7B62-40C3-BE67-667370599048Q27851554-8AB77DE2-78DF-4E18-BBD6-B54241F2EAB8Q27852678-F20583C0-99FE-475B-8080-A9A4AE6B5CAAQ27853152-AA1D1BAB-F218-42B3-BAD5-9B7815C8C5B7Q27853338-D1745646-20DA-4295-A403-293ADEE916DDQ27860519-3F2DD17E-DBD2-4B17-AF93-F3377C0738C5Q28189311-632485EA-CCA9-4D3B-A01D-0ED95C23615EQ28201328-AD9A8168-CB95-440B-A6F4-DD6A374C254DQ28201693-F70CEA76-A485-45B4-B27D-13F29FAC48BDQ28245028-B9EE0BDD-0D82-4252-8B7A-B6761612BB14Q28258565-206F3EA9-5F77-4F10-88E8-EAF6324F3A34Q28267128-50FA7D6E-DB00-4B84-B020-4681549F5995Q28268169-9469FC96-3378-4FE3-A1F7-C09787972099Q28276782-518D3FE6-55AA-476C-9A66-12E7AE502E75
P50
description
British biochemist
@en
biochemicus
@nl
name
Alan Ashworth
@ast
Alan Ashworth
@de
Alan Ashworth
@en
Alan Ashworth
@es
Alan Ashworth
@fr
Alan Ashworth
@nl
Alan Ashworth
@sl
type
label
Alan Ashworth
@ast
Alan Ashworth
@de
Alan Ashworth
@en
Alan Ashworth
@es
Alan Ashworth
@fr
Alan Ashworth
@nl
Alan Ashworth
@sl
prefLabel
Alan Ashworth
@ast
Alan Ashworth
@de
Alan Ashworth
@en
Alan Ashworth
@es
Alan Ashworth
@fr
Alan Ashworth
@nl
Alan Ashworth
@sl
P166
P106
P1153
35379025100
P185
P19
P2070
alan-ashworth-11011
P21
P31
P463
P569
1960-08-26T00:00:00Z